Trademark Search in Canada

NURYLBO

View On IC.GC.CA

CANCELLED

Last Applicant/ Owned by

OVID THERAPEUTICS INC.

1460 BroadwayNew York NY 10036

Serial Number

2034925 filed on 13^th May 2020

Registration Number

TMA1158103 registered on 28^th Dec 2022

Registration expiry Date

13^th May 2030

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

K1P1J9

NURYLBO

Trademark usage description

pharmaceutical preparations for the treatment of developmental disorders, namely, angelman syndrome, fragile x syndrome, epilepsy and seizure disorder Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of developmental disorders, namely, Angelman syndrome, Fragile X syndrome, epilepsy and seizure disorders; pharmaceutical preparations for the treatment of neurological disorders, namely, Angelman syndrome, Fragile X syndrome, epilepsy and seizure disorders.

Classification kind code

Mark Details

Serial Number

2034925

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 27^th Jan 2022	Agent Changed
Submitted for opposition 22 on 30^th Aug 2021	Search Recorded
Submitted for opposition 20 on 30^th Aug 2021	Examiner's First Report
Submitted for opposition 223 on 30^th Aug 2021	Total Provisional Refusal
Submitted for opposition 256 on 19^th Apr 2021	Notification of Possible Opposition Sent
Submitted for opposition 257 on 18^th Jun 2020	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 17^th Jun 2020	Created
Submitted for opposition 31 on 17^th Jun 2020	Formalized
Submitted for opposition 30 on 13^th May 2020	Filed
Submitted for opposition 228 on 13^th May 2020	International Registration